menu
    • menu
    [{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"HTL0018318","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Allergan Aesthetics","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Allergan Aesthetics"}]

    Find Clinical Drug Pipeline Developments & Deals for HTL0018318

    Menu

    HTL0018318

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sosei Heptares

                            Japan arrow
                            IMCAS Asia
                            Not Confirmed

                            Sosei Heptares

                            Japan arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HTL0018318

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Allergan Aesthetics

                            Deal Size : $3,290.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs

                            Details : AbbVie has notified that it will be returning to Sosei Heptares all assets in development under the program including HTL0018318, all intellectual property licensed by Sosei Heptares to Allergan, and all clinical and preclinical data generated under the ...

                            Product Name : HTL0018318

                            Product Type : Other Small Molecule

                            Upfront Cash : $125.0 million

                            May 01, 2021

                            Lead Product(s) : HTL0018318

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Allergan Aesthetics

                            Deal Size : $3,290.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth